SFRP1 repression in prostate cancer is triggered by two different epigenetic mechanisms-Reference-Cited by-同舟云学术

SFRP1 repression in prostate cancer is triggered by two different epigenetic mechanisms

Published:2016-11 Issue:2 Volume:593 Page:292-301
ISSN:0378-1119
Container-title:Gene
language:en
Short-container-title:Gene

Author:

García-Tobilla Pilar,Solórzano Susana R.,Salido-Guadarrama Iván,González-Covarrubias Vanessa,Morales-Montor Gustavo,Díaz-Otañez Carlos E.,Rodríguez-Dorantes Mauricio

Funder

CONACYT

Publisher

Elsevier BV

Subject

Genetics,General Medicine

Reference50 articles.

1. Is there evidence of a relationship between benign prostatic hyperplasia and prostate cancer? Findings of a literature review;Alcaraz;Eur. Urol.,2009

2. DNA methylation and methyl-CpG binding proteins: developmental requirements and function;Bogdanovic;Chromosoma,2009

3. Beyond Wnt inhibition: new functions of secreted frizzled-related proteins in development and disease;Bovolenta;J. Cell Sci.,2008

4. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data;Cerami;Cancer Discov.,2012

5. EZH2 dependent H3K27me3 is involved in epigenetic silencing of ID4 in prostate cancer;Chinaranagari;Oncotarget,2014

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. LncRNA DLG5-AS1 facilitates breast cancer cell proliferation and invasion by promoting EZH2-mediated transcriptional silencing of SFRP1;Archives of Biochemistry and Biophysics;2024-06

2. MiR26a reverses enzalutamide resistance in a bone-tumor targeted system with an enhanced effect on bone metastatic CRPC;Journal of Nanobiotechnology;2024-04-02

3. MiR26a Reverses Enzalutamide Resistance in a Bone-Tumor Targeted System with an Enhanced Effect on Bone Metastatic CRPC;2024-01-12

4. Concentration of Secreted Frizzled-Related Proteins (SFRPs) in Non-Small Cell Lung Carcinoma Subtypes—A Preliminary Study;Current Oncology;2023-11-18

5. Identification of tumor-agnostic biomarkers for predicting prostate cancer progression and biochemical recurrence;Frontiers in Oncology;2023-10-26